Caracterizaci?n de c?lulas madre perivasculares y c?lulas estromales mesenquimales de tejido adiposo de caballos

 

Authors
Pes?ntez Valdivieso, Juan Jos?
Format
MasterThesis
Status
publishedVersion
Description

The physical demands placed on sport horses not only during competition but also training makes them prone to musculoskeletal injuries. Current therapy does not always heal these injuries completely, so many horses have to be retired from competition or euthanized. This in turn affects the equine industry and constitutes an animal welfare issue. A promising alternative is the use of stem cells. Nonetheless, this novel therapy in veterinary practice is still limited because of the usage of heterogeneous preparations of cells and inconclusive knowledge of the stem cell physiology. Adipose tissue constitutes a renewable and accessible source of MSCs. Moreover, previous research shows that perivascular stem cells are the in vivo equivalent of MSCs. In this study, we characterised the phenotype of stromal vascular fraction-MSCs (SVF-MSCs) as well as cells sorted for CD34 and CD146 by exploring their gene expression, RT-qPCR was used in order to demonstrate the presence of commonly recognized MSCs markers, pericytes markers, lack of haematopoietic and endothelial marker in the culture cells. The fibroblastoid colony-forming unit capacity of the cells was also confirmed by seeding them at low density. We were also able to differentiate these cell types into osteo-, chondro-, and adipogenic lineages which is a characteristic that distinguishes them. Finally, we induced them to differentiate into skeletal myocytes creating a new line of research that should be exploited due to its usefulness in future clinical applications. The results obtained in this study shows that purified MSCs from equines vasculature express stem cell and pericyte markers, have a clonogenic potential and have a tri-lineage potential; therefore, constitute a cellular source for regenerative medicine.
Las demandas f?sica a las que son sometidos los caballos deportivos no solo durante competencias sino tambi?n durante entrenamientos los hacen propensos a lesiones musculoesquel?ticas. Las terapias actuales no curan totalmente estas lesiones, por esto muchos caballos tienen que ser retirados de competencia o incluso eutanasiados. Esto a su vez afecta a la industria equina y constituye un problema de bienestar animal. Una alternativa prometedora es el uso de c?lulas madre. Sin embargo, esta terapia novedosa es a?n limitada en medicina veterianaria por el uso de preparaciones celulares heterog?neas y falta de conocimientos sobre c?lulas madre. El tejido adiposo constituye una fuente renovable y asequible de c?lulas madre mesenquimales (CMM). Adem?s, investigaciones previas muestran que c?lulas madre perivasculares (CMP) son el equivalente in vivo de CMM. En este estudio, caracterizamos fenot?picamente CMM de la fracci?n estromal vascular (CMM-FEV) as? como c?lulas seleccionadas para CD34 y CD146 explorando su expresi?n gen?tica. RT-qPCR fue usado para demostrar la presencia de marcadores celulares para CMM, pericitos, y la ausencia de marcadores hematopoy?ticos y endoteliales. La capacidad de formar colonias de las c?lulas fue demostrada al sembrarlas a baja densidad. Pudimos diferenciar estas c?lulas en osteo-, condro- y adipocitos lo cual es una caracter?stica que distingue a las CMM. Finalmente, las inducimos a diferenciarse en c?lulas musculares esquel?ticas que es una nueva l?nea de investigaci?n que debe ser explotada por sus aplicaciones cl?nicas. Los resultados obtenidos en esta investigaci?n, muestran que CMM asiladas de la vasculatura expresan marcadores de c?lulas madre y pericitos, tiene potencial clonog?nico y capacidad de diferenciaci?n; por consiguiente, constituyen una fuente celular para medicina regenerativa.

Publication Year
2015
Language
eng
Topic
MEDICINA VETERINARIA
MEDICINA REGENERATIVA
BIOLOG?A DEL DESARROLLO
EQUINOS
C?LULAS MADRE MESENQUIMALES
Repository
Repositorio SENESCYT
Get full text
http://repositorio.educacionsuperior.gob.ec/handle/28000/1821
Rights
openAccess
License